Table 5.

Univariate Cox hazard analysis of factors associated with overall survival after second-line chemotherapy

Factors	Univariate			Multivariate
	HR	95% CI	P	HR	95% CI	P
Age (years)
<75 vs ≥75	0.91	0.48–1.72	0.77
Sex
Male vs female	0.57	0.22–1.47	0.25
ECOG PS
0–1 vs 2–4	3.11	1.66–5.83	<0.01	2.12	1.02–4.41	0.04
Stage
<IIIB vs IV	2.04	1.07–3.89	0.03	1.25	0.60–2.63	0.55
BMI (kg/m2)
≥18.5 vs <18.5	1.48	0.78–2.82	0.23
Leukocyte (×103 cells/μL)	1.08	1.00–1.16	0.05
Neutrophil (×103 cells/μL)a	1.11	1.03–1.19	<0.01	1.08	0.94–1.23	0.27
Lymphocyte (×103 cells/μL)a	0.49	0.29–0.85	0.01	0.45	0.22–0.92	0.03
Monocyte (×102 cells/μL)	1.10	0.98–1.23	0.12
Hemoglobin (mg/dL)b	0.76	0.65–0.89	<0.01	0.92	0.75–1.12	0.39
Red cell distribution width (%)b	1.34	1.15–1.62	<0.01	1.17	0.91–1.50	0.22
Platelet (×105 cells/μL)	1.16	0.81–1.66	0.41
Serum sodium (mEq/L)	0.89	0.82–0.98	0.01	0.93	0.84–1.04	0.22
LDH (×102 IU/L)	1.10	1.01–1.19	0.03	1.05	0.87–1.25	0.63
ALP (×102 IU/L)	1.18	1.02–1.36	0.02	1.10	0.81–1.50	0.54
CRP (mg/dL)	1.11	1.03–1.18	<0.01	1.00	0.91–1.11	0.94
Interval between first- and second-line chemotherapy (months)c	0.88	0.80–0.95	<0.01	0.94	0.86–1.0.	0.17

Notes: Coded as 1 (age ≥75 years, female, ECOG PS 2–4, stage IV, BMI <18.5 kg/m²) and as 0 (age <75 years, male, ECOG PS 0–1, stage I–III, BMI ≥18.5 kg/m²).

^aNo significant correlation was found between neutrophil and lymphocyte counts (r=0.09, 95% CI –0.16 to 0.33, P=0.48).

^bThere was a significant inverse correlation between hemoglobin and red cell distribution width (r=−0.33, 95% CI –0.53 to –0.09, P<0.01).

^cFrom the start of first-line chemotherapy to the start of second-line chemotherapy.

Abbreviations: ALP, alkaline phosphatase; BMI, body mass index; CI, confidence interval; CRP, C-reactive protein; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; LDH, lactate dehydrogenase; PS, performance status.